Abstract:OBJECTIVE:To evaluate long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy using optical coherence tomography. METHODS:A retrospective, interventional case series. Thirty-five eyes of 32 patients (35 eyes) with chronic central serous chorioretinopathy were included, with CSC durations from 6 to 60 months. Patients treated with half-dose verteporfin (3 mg/m(2)) PDT were followed up for 24 months. Best-corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT) pre and post-treatment were all examined to observe the anatomic and functional changes. OCT findings highlighted the alterations of the ellipsoid zone (EZ), the interdigitation zone (IZ) and the central neural retina thickness (CNT) from 3 month to 24 month post-treatment. Regression analysis was applied to determine the correlation between the visual function (BCVA) and structure status (EZ, IZ, CNT). RESULTS:Thirty-five eyes of 32 patients with chronic CSC were treated with half-dose PDT. The logMAR BCVA was 0.53±0.36 at baseline, 0.49±0.39 at 3 months and 0.15±0.38 at 24 months post-PDT. There was no statistical significance between baseline and 3 month BCVA (t=1.952, P>0.05). There existed statistical significance between baseline and 24 month BCVA(t=10.761, P<0.01) as well as 3month and 24 month BCVA(t=8.930, P<0.01). OCT demonstrated the recovery of EZ and IZ. Statistical differences of EZ and IZ integrity degree were found between the 3 month and 24 month (Z=-3.419, -4.082, P<0.01). The mean CNT was (126.8±34.9) μm at baseline. And it kept constant at 3 month [(125.6±34.3)μm] and the 24 month visit [(124.8±35.1)μm]. No statistical significance was found between any two values (t=-1.830, -1.569, 0.793, P>0.05). At baseline, 3 month and 24 month, there was negative correlation between logMAR BCVA and CNT (β=-0.604, -0.634, -0.685, P<0.01) . At 3 month and 24 month, negative correlation between logMAR BCVA and EZ as well as logMAR BCVA and IZ were also found(β=-0.376, -0.394, -0.628, -0.496, P<0.05). A complete resolution of subretinal fluid was noted in 94.3% eyes at 3 month, further increased to 100% eyes at 24 month. The mean session of PDT was 1.03±0.17. CONCLUSIONS:Half-dose PDT was safe and effective for chronic CSC both functionally and morphologically in the long term. Visual benefits may not appear in a short run, yet became remarkable in a long run. Visual benefits might be attributed to recovery of EZ and IZ.

A Two-Year Study of Diffused Retinal Pigment Epitheliopathy Treated with Half-Dose Photodynamic Therapy Guided by Simultaneous Angiography and Optical Coherence Tomography

Extensive Submacular Haemorrhage in Polypoidal Choroidal Vasculopathy Managed by Sequential Gas Displacement and Photodynamic Therapy: a Pilot Study of One‐year Follow Up

[Observation on Long-Term Efficacy of Half-Dose Photodynamic Therapy with Chronic Central Serous Chorioretinopathy Using Optical Coherence Tomography].

Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy

[Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].

Retinal Microstructure Based on Optical Coherence Tomography Predicts Visual Prognosis in Diabetic Macular Edema with Extended Intraretinal Cysts and Subretinal Fluid.

Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy

Retrospective study of low-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy

Clinical Observation of a Half Dose of Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy

Short-Term Retinal Sensitivity and Metamorphopsia Changes following Half-Fluence Photodynamic Therapy in Central Serous Chorioretinopathy

A randomized non-inferiority trial of 577nm subthreshold micropulse laser versus half-dose photodynamic therapy for acute central serous chorioretinopathy

The Relationship Between Foveal Outer Nuclear Layer Thickness in the Active and Resolved Phases of Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy

Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy

Retrospective study of 30％ and 50％ dose verteporfin photodynamic therapy versus anti-vascular endothelial growth factor for chronic central serous chorioretinopathy

Choroidal Neovascularization Emerged Right from the Focal Choroidal Excavation in Eyes with Central Serous Chorioretinopathy Post Half-Dose Photodynamic Therapy: a Case Report

Optical coherence tomography angiography–guided vs indocyanine green angiography–guided half-dose photodynamic therapy for acute central serous chorioretinopathy: 6-month randomized trial results

Threshold Thickness of Foveal Outer Nuclear Layer Associated with Outcomes of Photodynamic Therapy in Central Serous Chorioretinopathy

Clinical predictive factors and imaging biomarkers of treatment response to half dose PDT in patients with chronic central serous chorioretinopathy

Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy

OCTA Evaluation of Treatment-Naïve Flat Irregular PED (Fiped)-Associated CNV in Chronic Central Serous Chorioretinopathy Before and after Half-Dose PDT.

Changes in the Foveal Outer Nuclear Layer of Central Serous Chorioretinopathy Patients over the Disease Course and Their Response to Photodynamic Therapy